Thermo Fisher Scientific Inc. and Qatar Genome Program (QGP), a member of Qatar Foundation, partnered to speed up genomic research and clinical applications of predictive genomics in Qatar to accelerate the benefits of precision medicine across Arab populations worldwide. By combining whole genome sequencing data with an Axiom custom genotyping array for Pan-Arab populations, this partnership aims to advance scientific research and provide insights into conditions such as diabetes, cardiovascular and metabolic disorders, autism, and other genetic disorders.
UK Biobank Limited released the Whole Genome Sequencing (WGS) data of 200,000 UK Biobank participants for research use. Through these steps, researchers are estimated to understand the genetic factors of the disease and accelerate advanced drug discovery work.
Author Credits: Radhika Gupta, Shivam Bhutani